Continuous Glucose Monitoring Initiation at Hospital Discharge

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-13

Study Completion Date

2022-06-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to look at feasibility (the likelihood) of continued use of the FreeStyle Libre 2 Continuous glucose monitor (CGM) when started at the time of hospital discharge in patients with poorly controlled diabetes and to look at the effects of CGM use on blood glucose control and quality of life. Additional information will be collected to determine the barriers to continuing CGM use after discharge. The investigators will also collect information to see how well blood glucose has been controlled after discharge while utilizing the CGM.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Temporary Use of a Continuous Glucose Monitoring System as an Adjunct to Lifestyle Medicine Education

NCT04306848

Blood Glucose Profile

WITHDRAWN NA

Develop Novel Methods to Display, Report and Analyze CGM Data for Clinical Decision-Making in People With Diabetes

NCT00465881

Diabetes Glucose Variability CGM

COMPLETED

Satisfaction of Hospitalized Diabetic Patients Using a Continuous Glucose Monitoring System

NCT03411460

Insulin-Dependent Diabetes

TERMINATED NA

FreeStyle Libre 2 Discharge Trial

NCT05822232

Diabetes Mellitus, Type 2 Hypoglycemia

UNKNOWN NA

A Study to Evaluate Continuous Glucose Monitor in Hospitalized, Post-operative Patients With Diabetes Mellitus

NCT04845685

Diabetes Mellitus

SUSPENDED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

VISIT/PHONE CALL WHAT WILL HAPPEN? (estimated time) \[window\]

Screening Visit (\~45 minutes) Review consent form and obtain consent Complete questionnaire, obtain diabetes history Day of Discharge (\~1 hour) Complete FreeStyle Libre 2 CGM education Attach FreeStyle Libre 2 CGM sensor to arm Within 1-3 weeks from discharge Phone Call (\~30 minutes) Questions regarding use of FreeStyle Libre 2 CGM Current diabetes regimen Adverse Events Reminder to take FreeStyle Libre 2 CGM sensor prescription to pharmacy to be filled

1 \& 3 Month Phone Call (\~45 minutes) \[+/- 5 days\] Questions regarding use of FreeStyle Libre 2 CGM Current diabetes regimen Complete questionnaire Adverse Events 6 Month Phone Call (\~15 minutes) \[+/- 10 days\] Questions regarding use of FreeStyle Libre 2 CGM Barriers to FreeStyle Libre 2 CGM use

Validated Instruments: Diabetes self-management Questionnaire (DMSQ)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes Type2 Diabetes Hyperglycemia Hypoglycemia Hypoglycemia Unawareness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CGM Intervention

All eligible patients will receive a Continuous Glucose Monitor (CGM) prior to hospital discharge after signing an informed consent.

Group Type EXPERIMENTAL

CGM4Home

Intervention Type DEVICE

FreeStyle Libre 2 Continuous Glucose Monitoring System manufactured by Abbott

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CGM4Home

FreeStyle Libre 2 Continuous Glucose Monitoring System manufactured by Abbott

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18 years of age or older
2. Have diabetes (type 1 diabetes mellitus, type 2 diabetes mellitus, cystic fibrosis related diabetes mellitus)
3. Hemoglobin A1c greater than or equal to 8.0% or history of hypoglycemia unawareness
4. Able and willing to sign informed consent form
5. Have a valid telephone number
6. Willing to purchase FreeStyle Libre 2 CGM sensors out of pocket after discharge from hospital (when insurance coverage isn't available)

Exclusion Criteria

1. Unable to sign informed consent form
2. Have altered mental status
3. Unable to manage diabetes independently at home
4. Have utilized CGM in the past
5. Pregnancy
6. New steroid-induced hyperglycemia
7. Unwilling to participate in the study
8. Have kidney disease requiring hemodialysis
9. Taking high doses of vitamin C daily (greater than 500 mg every day)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No